Edition:
United States

PTC Therapeutics Inc (PTCT.OQ)

PTCT.OQ on NASDAQ Stock Exchange Global Select Market

34.00USD
25 Jun 2018
Change (% chg)

$-2.01 (-5.58%)
Prev Close
$36.01
Open
$35.33
Day's High
$35.52
Day's Low
$34.00
Volume
36,683
Avg. Vol
390,044
52-wk High
$52.95
52-wk Low
$14.57

Chart for

About

PTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered... (more)

Overall

Beta: 1.70
Market Cap(Mil.): $1,672.51
Shares Outstanding(Mil.): 46.45
Dividend: --
Yield (%): --

Financials

  PTCT.OQ Industry Sector
P/E (TTM): -- 248.83 34.14
EPS (TTM): -0.58 -- --
ROI: -9.06 -5.25 13.10
ROE: -18.40 -6.83 15.09

Roche SMA drug shines in study as costly new therapies advance

ZURICH A drug being co-developed by Roche to treat spinal muscular atrophy (SMA) helped improve development scores in babies with the genetic disease, a study released on Monday showed, as the race heats up for therapies destined to be among the drug industry's most expensive.

Jun 18 2018

Roche SMA drug shines in study as costly new therapies advance

ZURICH, June 18 A drug being co-developed by Roche to treat spinal muscular atrophy (SMA) helped improve development scores in babies with the genetic disease, a study released on Monday showed, as the race heats up for therapies destined to be among the drug industry's most expensive.

Jun 18 2018

BRIEF-PTC Therapeutics Reports Q1 Loss Per Share $0.46

* PTC THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

May 09 2018

BRIEF-PTC Therapeutics announces presentation of preliminary data from Part 1,dose finding portion, of ongoing FIREFISH clinical trial

* PRELIMINARY CLINICAL DATA FROM FIREFISH TRIAL IN TYPE 1 SMA PATIENTS PRESENTED AT THE AMERICAN ACADEMY OF NEUROLOGY ANNUAL MEETING

Apr 24 2018

BRIEF-PTC Therapeutics Prices Public Offering Of Common Stock At $27.04 Per Share​

* PTC THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

Mar 28 2018

BRIEF-PTC Therapeutics Announces Proposed Public Offering Of Common Stock

* PTC THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Mar 27 2018

BRIEF-Ptc Therapeutics Says ‍Firefish Study Of RG7916 In Type 1 Spinal Muscular Atrophy Patients Transitioned Into Pivotal Phase With Dosing First Patient​

* PTC THERAPEUTICS INC - ‍FIREFISH STUDY OF RG7916 IN TYPE 1 SPINAL MUSCULAR ATROPHY PATIENTS TRANSITIONED INTO PIVOTAL PHASE WITH DOSING FIRST PATIENT​ Source text for Eikon: Further company coverage:

Mar 15 2018

BRIEF-PTC Therapeutics Q4 Revenue $78.0 Million

* ‍TOTAL REVENUES FOR Q4 OF 2017 WERE $78.0 MILLION COMPARED TO $25.2 MILLION IN Q4 OF 2016​

Mar 06 2018

BRIEF-Boxer Capital Reports 6 Pct Passive Stake In ‍PTC Therapeutics​

* BOXER CAPITAL, LLC REPORTS 6 PERCENT PASSIVE STAKE IN ‍ PTC THERAPEUTICS, INC AS OF JANUARY 16, 2018 - SEC FILING​ Source text - http://bit.ly/2FkWr0i Further company coverage:

Jan 26 2018

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $36.24 -0.27
Merck & Co., Inc. (MRK.N) $61.10 -0.37
Bayer AG (BAYGn.DE) €96.64 -2.20
Bayer AG (BAYE.F) -- --

Earnings vs. Estimates